FindTrial
Sign In

Effects of different neoadjuvant or conversion therapies on liver function and prognosis of patients with liver cancer

Effects of different neoadjuvant or conversion therapies on liver function and prognosis of patients with liver cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076241
Enrollment
Unknown
Registered
2023-09-28
Start date
2023-10-01
Completion date
Unknown
Last updated
2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer

Interventions

hepatic arterial infusion chemotherapy group (hepatic arterial infusion chemotherapy):None
transcatheter arterial chemoembolization group (transcatheter arterial chemoembolization):None

Sponsors

Department of Liver Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with liver cancer who received neoadjuvant/conversion therapies at Sun Yat-sen University Cancer Cente

Exclusion criteria

Exclusion criteria: Not pathological diagnosed as malignant liver cancer. Not received neoadjuvant/conversion therapies. Previously received other therapies.

Design outcomes

Primary

MeasureTime frame
Indocyanine green (ICG) clearance test;—

Secondary

MeasureTime frame
overall survival;recurrence-free survival;Biochemical tests;—

Countries

China

Contacts

Public ContactXu Li

Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine

xuli@sysucc.org.cn+86 20 8734 3582

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026